Phase II Safety Study of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as Second-line Therapy in Patients With Hepatocellular Carcinoma

Bolondi, L. and Tak, W. Y. and Gasbarrini, A. and Santoro, A. and Colombo, M. and Lim, H. Y. and Mazzaferro, V. and Wiest, R. and Reig, M. and Bruix, J. (2011) Phase II Safety Study of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as Second-line Therapy in Patients With Hepatocellular Carcinoma. EUROPEAN JOURNAL OF CANCER, 47 (Suppl1). S464. ISSN 0959-8049

Full text not available from this repository.
Item Type: Article
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin I
Depositing User: Petra Gürster
Date Deposited: 05 May 2020 07:30
Last Modified: 05 May 2020 07:30
URI: https://pred.uni-regensburg.de/id/eprint/20228

Actions (login required)

View Item View Item